Multiple Sclerosis Journal - Experimental, Translational and Clinical最新文献

筛选
英文 中文
Validity and reliability of fatigue scale for motor and cognitive functions (FSMC) in an Iranian population of people with multiple sclerosis. 伊朗多发性硬化症患者运动和认知功能疲劳量表(FSMC)的效度和可靠性
IF 2.3
Multiple Sclerosis Journal - Experimental, Translational and Clinical Pub Date : 2025-09-24 eCollection Date: 2025-07-01 DOI: 10.1177/20552173251375781
Farinaz Tabibian, Armin Adibi, Ali Motahharynia, Kiarash Azimzadeh, Ahmad Pourmohammadi, Fatemeh Rajabi, Parastoo Golshiri, Iman Adibi
{"title":"Validity and reliability of fatigue scale for motor and cognitive functions (FSMC) in an Iranian population of people with multiple sclerosis.","authors":"Farinaz Tabibian, Armin Adibi, Ali Motahharynia, Kiarash Azimzadeh, Ahmad Pourmohammadi, Fatemeh Rajabi, Parastoo Golshiri, Iman Adibi","doi":"10.1177/20552173251375781","DOIUrl":"10.1177/20552173251375781","url":null,"abstract":"<p><strong>Introduction: </strong>Multiple sclerosis (MS) is a central nervous system disorder and is frequently associated with fatigue. The Fatigue Scale for Motor and Cognitive Functions (FSMC) is an instrument to assess both motor and cognitive dimensions of fatigue in MS.</p><p><strong>Methods: </strong>The study included 60 MS patients who completed the Persian version of the Modified Fatigue Impact Scale (MFIS) and a translated version of FSMC questionnaire. The FSMC was translated using standardized forward-backward translation, expert review, and patient feedback to ensure linguistic and conceptual validity. To evaluate test-retest reliability, participants completed the translated version of FSMC again after two weeks. Content validity was examined by a panel of eight experts.</p><p><strong>Results: </strong>Sixty individuals with a mean age of 36.36 ± 9.7 years and an Expanded Disability Status Scale score of 3.00 ± 2.0 were enrolled in this study. Fifty-one (85%) of the participants were female. The Persian FSMC demonstrated strong content validity (Content Validity Index: 0.875-1.00; content validity ratio: 0.75-1.00). Internal consistency was excellent (Cronbach's alpha = 0.964). Test-retest reliability was strong for average scores (intraclass correlation coefficient (intraclass correlation coefficient (ICC) = 0.979), though fair to good for single measures (ICC = 0.540). Convergent validity was supported by strong correlations with MFIS scores (FSMC-total: <i>r</i> = 0.88; motor: <i>r</i> = 0.87; cognitive: <i>r</i> = 0.85; all <i>p</i> < .001). No floor/ceiling effects were observed.</p><p><strong>Conclusions: </strong>The Persian version of the FSMC is a valid and reliable instrument for assessing fatigue in Iranian patients with MS. With strong psychometric properties, it is well-suited for clinical and research use in Persian-speaking populations.</p>","PeriodicalId":18961,"journal":{"name":"Multiple Sclerosis Journal - Experimental, Translational and Clinical","volume":"11 3","pages":"20552173251375781"},"PeriodicalIF":2.3,"publicationDate":"2025-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12461057/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145186419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The presence of a paramagnetic phase rim in multiple sclerosis is linked to lesion age: An exploratory study. 多发性硬化症中顺磁相环的存在与病变年龄有关:一项探索性研究。
IF 2.3
Multiple Sclerosis Journal - Experimental, Translational and Clinical Pub Date : 2025-09-24 eCollection Date: 2025-07-01 DOI: 10.1177/20552173251378788
Samuel Klistorner, Tatiana Usnich, Margareta A Clarke, Deborah Pareto, Àlex Rovira, Friedemann Paul, Michael Barnett, Alexander Klistorner
{"title":"The presence of a paramagnetic phase rim in multiple sclerosis is linked to lesion age: An exploratory study.","authors":"Samuel Klistorner, Tatiana Usnich, Margareta A Clarke, Deborah Pareto, Àlex Rovira, Friedemann Paul, Michael Barnett, Alexander Klistorner","doi":"10.1177/20552173251378788","DOIUrl":"10.1177/20552173251378788","url":null,"abstract":"<p><strong>Background: </strong>In relapsing-remitting multiple sclerosis (RRMS), smouldering inflammation at the rims of chronic active lesions is increasingly recognised as a key driver of disease progression. Paramagnetic rim lesions (PRLs), detected using susceptibility-weighted imaging, have emerged as a potential biomarker of this chronic inflammatory activity. However, their clinical relevance and relationship to lesion-specific features such as size and age remain poorly understood.</p><p><strong>Objective: </strong>To investigate the association between PRL presence and clinical/radiological measures of disease progression, and to explore how PRLs relate to lesion size and age.</p><p><strong>Methods: </strong>A retrospective study of 60 RRMS patients with over 5 years of magnetic resonance imaging data was conducted using susceptibility-weighted angiography. Lesions larger than 100 mm<sup>3</sup> were analysed.</p><p><strong>Results: </strong>PRLs were present in 48% of patients and represented 13% of lesions. PRLs were significantly larger and more structurally damaged, with volume correlating with EDSS change and brain atrophy. All lesions formed within 5 years of imaging were PRLs. This finding was validated in two independent international cohorts. Moreover, the proportion of rim-positive lesions decreased as lesion age increased.</p><p><strong>Conclusion: </strong>PRLs are closely linked to lesion age and early development, supporting their role as a dynamic biomarker of lesion activity in multiple sclerosis.</p>","PeriodicalId":18961,"journal":{"name":"Multiple Sclerosis Journal - Experimental, Translational and Clinical","volume":"11 3","pages":"20552173251378788"},"PeriodicalIF":2.3,"publicationDate":"2025-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12461053/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145186362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Factors associated with cognitive impairment in patients with neuromyelitis optica spectrum disorders from Mexico. 墨西哥视神经脊髓炎谱系障碍患者认知障碍相关因素
IF 2.3
Multiple Sclerosis Journal - Experimental, Translational and Clinical Pub Date : 2025-09-19 eCollection Date: 2025-07-01 DOI: 10.1177/20552173251378801
Edgar R Valdivia-Tangarife, Fabiola Gonzalez-Ponce, Alejandra Morlett-Paredes, Jazmin Marquez-Pedroza, Teresita Villaseñor-Cabrera, Jorge I Gámez-Nava, Laura González-López, Mario A Mireles-Ramírez, Nayeli A Sánchez-Rosales, Martha Rocio Hernandez-Preciado, Francia Franco-Sánchez, Miguel Ángel Macías-Islas
{"title":"Factors associated with cognitive impairment in patients with neuromyelitis optica spectrum disorders from Mexico.","authors":"Edgar R Valdivia-Tangarife, Fabiola Gonzalez-Ponce, Alejandra Morlett-Paredes, Jazmin Marquez-Pedroza, Teresita Villaseñor-Cabrera, Jorge I Gámez-Nava, Laura González-López, Mario A Mireles-Ramírez, Nayeli A Sánchez-Rosales, Martha Rocio Hernandez-Preciado, Francia Franco-Sánchez, Miguel Ángel Macías-Islas","doi":"10.1177/20552173251378801","DOIUrl":"10.1177/20552173251378801","url":null,"abstract":"<p><p><b>Background:</b> Patients with neuromyelitis optica spectrum disorders (NMOSD) often experience significant functional limitation, high rates of disability, and cognitive impairment (CI). The objective of this study was evaluating the factors associated with CI in patients diagnosed with NMOSD in Mexico. <b>Methods:</b> The study was cross-sectional in design. We included 65 NMOSD patients (34 NMOSD with CI and 31 NMOSD without CI). We utilized the Brief International Cognitive Assessment for Multiple Sclerosis to identify CI in NMOSD patients. Logistic regression was applied to identify the factors associated with CI. <b>Results:</b> Factors associated with CI in the crude analysis were education level (⩽6 years of schooling; odds ratio (OR) 4.37, 95% confidence interval (CI) 1.41-13.52, <i>p</i> = 0.010), disease duration (⩾60 months; OR 8.22, 95% CI 2.68-25.20, <i>p</i> < 0.001), time from onset to diagnosis (⩾12 months; OR 3.70, 95% CI 1.21-11.31, <i>p</i> = 0.022), brain lesion (on magnetic resonance imaging before azathioprine or rituximab; OR 3.46, 95% CI 1.20-10.00, <i>p</i> = 0.022), and relapses by NMOSD diagnosis (⩾4; OR 4.48, 95% CI 1.57-12.76, <i>p</i> = 0.005). Factors associated with CI in the adjusted analyses were education (⩽6 years; OR 5.92, 95% CI 1.57-22.23, <i>p</i> = 0.008), disease duration (⩾60 months; OR 5.73, 95% CI 1.69-19.40, <i>p</i> = 0.005), and relapses by NMOSD diagnosis (⩾4; OR 5.79, 95% CI 1.70-19.72, <i>p</i> = 0.005). <b>Conclusion:</b> One of the biggest factors associated with CI was relapse by NMOSD, specifically those with lower education levels and those with longer disease duration.</p>","PeriodicalId":18961,"journal":{"name":"Multiple Sclerosis Journal - Experimental, Translational and Clinical","volume":"11 3","pages":"20552173251378801"},"PeriodicalIF":2.3,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12449630/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145113898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Analysis of an innovative fluid biomarker panel for early prediction of progression independent of relapse activity in multiple sclerosis. 一种创新的液体生物标志物小组分析,用于早期预测多发性硬化症独立于复发活动的进展。
IF 2.3
Multiple Sclerosis Journal - Experimental, Translational and Clinical Pub Date : 2025-09-12 eCollection Date: 2025-07-01 DOI: 10.1177/20552173251372751
Edoardo Dalmato Schilke, Maura Frigo, Maria Letizia Fusco, Adele Cappellani, Diletta Cereda, Chiara Paola Zoia, Guido Cavaletti
{"title":"Analysis of an innovative fluid biomarker panel for early prediction of progression independent of relapse activity in multiple sclerosis.","authors":"Edoardo Dalmato Schilke, Maura Frigo, Maria Letizia Fusco, Adele Cappellani, Diletta Cereda, Chiara Paola Zoia, Guido Cavaletti","doi":"10.1177/20552173251372751","DOIUrl":"10.1177/20552173251372751","url":null,"abstract":"<p><strong>Background: </strong>Progression independent of relapse activity (PIRA) may occur in patients with relapsing multiple sclerosis (MS) and is a major contributor to disability accumulation.</p><p><strong>Objectives: </strong>We evaluated whether a panel of cerebrospinal fluid (CSF) biomarkers (neurofilament light chain (NfL), glial fibrillary acid protein (GFAP), total-Tau (T-Tau), ubiquitin C-terminal hydrolase 1 (UCHL-1), and the phospho-Tau (P-Tau)181/T-Tau ratio) at diagnosis could discriminate patients who will develop PIRA in early disease phases.</p><p><strong>Methods: </strong>CSF levels of NfL, GFAP, T-Tau, and UCHL-1 were measured with SIMOA, of P-Tau181, and the ratio P-Tau181/T-Tau with chemiluminescent immunoassay in 80 newly diagnosed MS patients who were followed up for three years with six-month Expanded Disability Status Scale (EDSS) assessments and yearly MRI scans.</p><p><strong>Results: </strong>Nineteen participants developing PIRA exhibited elevated GFAP and UCHL-1 levels, and reduced P-Tau181/T-Tau ratio. These biomarkers remained significant predictors of the outcome after adjusting for confounders, particularly older age at onset and higher baseline EDSS. Additionally, we identified moderate positive correlations between NfL-GFAP, NfL-UCHL-1, and GFAP-UCHL-1 levels, and moderate negative correlations between P-Tau181/T-Tau ratio and NfL, GFAP, and UCHL-1 levels.</p><p><strong>Conclusions: </strong>The elevation of GFAP and UCHL-1 likely reflects the role of astrocytic activation, while the reduction of the P-Tau181/T-Tau ratio may indicate disrupted Tau metabolism in individuals at risk of PIRA. Our findings suggest that combining these innovative biomarkers with clinical risk factors could improve early prognostic accuracy.</p>","PeriodicalId":18961,"journal":{"name":"Multiple Sclerosis Journal - Experimental, Translational and Clinical","volume":"11 3","pages":"20552173251372751"},"PeriodicalIF":2.3,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12432306/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145065348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Relapse or no relapse in multiple sclerosis: Can disease activity biomarkers support the clinician? 多发性硬化症复发或不复发:疾病活动性生物标志物能支持临床医生的判断吗?
IF 2.3
Multiple Sclerosis Journal - Experimental, Translational and Clinical Pub Date : 2025-09-02 eCollection Date: 2025-07-01 DOI: 10.1177/20552173251370830
Jeske van Pamelen, Marleen J A Koel-Simmelink, Birgit I Lissenberg, Edo P J Arnoldus, Janet de Beukelaar, Judith van Vliet, Joep Killestein, Charlotte E Teunissen, Leo H Visser
{"title":"Relapse or no relapse in multiple sclerosis: Can disease activity biomarkers support the clinician?","authors":"Jeske van Pamelen, Marleen J A Koel-Simmelink, Birgit I Lissenberg, Edo P J Arnoldus, Janet de Beukelaar, Judith van Vliet, Joep Killestein, Charlotte E Teunissen, Leo H Visser","doi":"10.1177/20552173251370830","DOIUrl":"10.1177/20552173251370830","url":null,"abstract":"<p><strong>Background: </strong>In relapsing-remitting multiple sclerosis (RRMS), the assessment of clinical disease activity can be challenging.</p><p><strong>Objectives: </strong>To determine the diagnostic potential of serum neurofilament light (sNfL) and glial fibrillary acidic protein (sGFAP) to distinguish a relapse from other causes of deterioration.</p><p><strong>Methods: </strong>In this multicenter, prospective study, RRMS patients with new neurological symptoms in the last 14 days were followed for 12 weeks. A diagnosis was established by the treating physician or, when in doubt, a panel of experienced neurologists. Blood samples were taken at baseline and week 12.</p><p><strong>Results: </strong>A total of 65 patients were included. At baseline, patients with a clear relapse had a significantly higher median sNfL (14.6 pg/mL) than those with a clear other cause (9.5 pg/mL, <i>p</i> = 0.004). Although not significant after correction for multiple testing, median sGFAP was also higher in relapse patients (73.0 vs 64.6 pg/mL, <i>p</i> = 0.036). An sNfL value below 6.0 pg/mL had a high sensitivity (67% at baseline (CI 22.3-95.7%) and 100% at follow-up (CI 54.1-100%)) to rule out a relapse.</p><p><strong>Conclusions: </strong>Analysis of sNfL level can be useful as an add-on investigation to determine whether disease activity is present in patients with RRMS presenting with new symptoms.</p>","PeriodicalId":18961,"journal":{"name":"Multiple Sclerosis Journal - Experimental, Translational and Clinical","volume":"11 3","pages":"20552173251370830"},"PeriodicalIF":2.3,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12405697/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145001075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Letter to the editor regarding "Treatment persistence and clinical outcomes in patients starting B cell depleting therapies within the Swiss MS Cohort". 致编辑关于“瑞士多发性硬化症队列中开始B细胞消耗治疗的患者的治疗持久性和临床结果”的信。
IF 2.3
Multiple Sclerosis Journal - Experimental, Translational and Clinical Pub Date : 2025-08-28 eCollection Date: 2025-07-01 DOI: 10.1177/20552173251370841
Joaquín Borrás-Blasco, Alejandro Valcuende-Rosique, Silvia Cornejo-Uixeda
{"title":"Letter to the editor regarding \"Treatment persistence and clinical outcomes in patients starting B cell depleting therapies within the Swiss MS Cohort\".","authors":"Joaquín Borrás-Blasco, Alejandro Valcuende-Rosique, Silvia Cornejo-Uixeda","doi":"10.1177/20552173251370841","DOIUrl":"10.1177/20552173251370841","url":null,"abstract":"","PeriodicalId":18961,"journal":{"name":"Multiple Sclerosis Journal - Experimental, Translational and Clinical","volume":"11 3","pages":"20552173251370841"},"PeriodicalIF":2.3,"publicationDate":"2025-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12394840/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144962009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diffusion tensor imaging in the SPRINT-MS clinical trial: Advancing trial methodology. SPRINT-MS临床试验中的弥散张量成像:改进试验方法学。
IF 2.3
Multiple Sclerosis Journal - Experimental, Translational and Clinical Pub Date : 2025-08-26 eCollection Date: 2025-07-01 DOI: 10.1177/20552173251361225
Ken Sakaie, Mengke Du, Nancy Obuchowski, Mark J Lowe, Jian Lin, Robert J Fox
{"title":"Diffusion tensor imaging in the SPRINT-MS clinical trial: Advancing trial methodology.","authors":"Ken Sakaie, Mengke Du, Nancy Obuchowski, Mark J Lowe, Jian Lin, Robert J Fox","doi":"10.1177/20552173251361225","DOIUrl":"10.1177/20552173251361225","url":null,"abstract":"<p><strong>Background: </strong>SPRINT-MS was a placebo-controlled phase 2 trial of ibudilast in secondary and primary progressive multiple sclerosis. The trial included multimodal imaging to assess brain tissue integrity. This contribution focuses on improved analysis methods of diffusion tensor imaging to refine its application in clinical trials.</p><p><strong>Objective: </strong>Reassess diffusion tensor imaging from the SPRINT-MS trial.</p><p><strong>Methods: </strong>Postprocessing incorporated corrections for bulk motion, eddy current distortion, outlier replacement, and intra-volume movement. The ICBM-DTI-81 white matter parcellation map was coregistered into native space. Six unilateral and 21 bilateral regions of interest were identified. Median radial diffusivity was the primary outcome measure for this analysis. A linear mixed-effects model was used to assess the interaction between time and treatment for the outcome measure with Holm correction for multiple comparisons.</p><p><strong>Results: </strong>Radial diffusivity in the cingulum and cerebellar peduncles showed a significant difference in rate of change between treatment and placebo groups (2.7-7.4 × 10<sup>-3</sup> mm<sup>2</sup>/s per 24-week time period, <i>p</i> < 0.04). Radial diffusivity was unchanged (declined) in the treatment (placebo) groups, consistent with preservation (deterioration) of tissue integrity.</p><p><strong>Conclusion: </strong>Our results suggest that the diffusion tensor imaging of the cingulum and cerebellar peduncles may be useful target outcome metrics in neuroprotective trials in progressive multiple sclerosis.</p>","PeriodicalId":18961,"journal":{"name":"Multiple Sclerosis Journal - Experimental, Translational and Clinical","volume":"11 3","pages":"20552173251361225"},"PeriodicalIF":2.3,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12381466/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144962077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Deep cervical lymph node volume decreases following B-cell depletion therapy. b细胞耗竭治疗后,颈深淋巴结体积减小。
IF 2.3
Multiple Sclerosis Journal - Experimental, Translational and Clinical Pub Date : 2025-08-25 eCollection Date: 2025-07-01 DOI: 10.1177/20552173251371743
Nikhil Lele, Sathish K Dundamadappa, Christopher C Hemond
{"title":"Deep cervical lymph node volume decreases following B-cell depletion therapy.","authors":"Nikhil Lele, Sathish K Dundamadappa, Christopher C Hemond","doi":"10.1177/20552173251371743","DOIUrl":"10.1177/20552173251371743","url":null,"abstract":"<p><p>The deep cervical lymph nodes (dCLNs) are sites of immune presentation and B-cell maturation from the brain, and potentially involved in mechanisms of neuroinflammation. We hypothesized a reduction in dCLN volume following B-cell depletion therapy. In a retrospective cohort, we segmented bilateral dCLN from T2-FLAIR MRI at \"prebaseline,\" \"baseline,\" and \"post-B-cell depletion\" timepoints. Using a multivariable mixed-effect regression model, we find no changes in dCLN volumes between prebaseline and baseline timepoints (<i>p</i> > 0.05), but a significant decrease of 158 mm<sup>3</sup> following ocrelizumab infusion (<i>t</i> = -3.3, <i>p</i> = 0.005). Baseline use of a disease-modifying therapy was also significantly associated with a smaller dCLN volume and attenuated the effects of B-cell depletion. These results are congruent with therapeutic mechanisms, although other alternative explanations for reductions in dCLN volumes cannot be ruled out based on this data. Deep CLN represent potential imaging biomarkers of pharmacological or clinical utility and warrant further investigation.</p>","PeriodicalId":18961,"journal":{"name":"Multiple Sclerosis Journal - Experimental, Translational and Clinical","volume":"11 3","pages":"20552173251371743"},"PeriodicalIF":2.3,"publicationDate":"2025-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12378606/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144961972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dermatologic findings after initiation of fingolimod in patients with multiple sclerosis: A real-world experience of five-year follow-up. 多发性硬化症患者开始使用芬戈莫德后的皮肤病学发现:一个真实世界的5年随访经验。
IF 2.3
Multiple Sclerosis Journal - Experimental, Translational and Clinical Pub Date : 2025-08-21 eCollection Date: 2025-07-01 DOI: 10.1177/20552173251369990
Monireh Samimi, Aida Sajedi, Sepideh Paybast, Nazanin Sadat Nabavi, Shahedeh Karimi, Sepideh Yazdanbakhsh, Mehran Gaffari, Abbas Najafian, Leila Faghani, Zahra Zolfaghari, Massoud Vosough, Seyed Massood Nabavi
{"title":"Dermatologic findings after initiation of fingolimod in patients with multiple sclerosis: A real-world experience of five-year follow-up.","authors":"Monireh Samimi, Aida Sajedi, Sepideh Paybast, Nazanin Sadat Nabavi, Shahedeh Karimi, Sepideh Yazdanbakhsh, Mehran Gaffari, Abbas Najafian, Leila Faghani, Zahra Zolfaghari, Massoud Vosough, Seyed Massood Nabavi","doi":"10.1177/20552173251369990","DOIUrl":"10.1177/20552173251369990","url":null,"abstract":"<p><strong>Background: </strong>Fingolimod was approved in 2010 for the treatment of relapsing-remitting multiple sclerosis, generally as second-line therapy. While its efficacy in reducing the relapse rate is well-recognized, the dermatologic complications of fingolimod remain unexplored. Herein, we aimed to report our experience with multiple sclerosis patients treated with fingolimod who underwent periodic dermatologic examinations.</p><p><strong>Materials and methods: </strong>A prospective cohort of 323 patients with multiple sclerosis treated with fingolimod were assessed for dermatologic manifestations over 60 months. The neurologic and dermatologic examinations were done biannually to identify and categorize skin-related adverse events.</p><p><strong>Results: </strong>Over a mean follow-up of 60 months, of the 323 patients, 32.19% (104 patients) developed skin abnormalities after a mean interval of 25.77 ± 24.36 months since fingolimod initiation. The majority of patients (91.34%) were female, with a mean age of 36.40 ± 7.45 years and a mean disease duration of 122 ± 58.56 months. The most common findings included melanocytic nevus (65.38%) and infectious lesions (11.53%). The severity of skin lesions varied, with most cases manageable with topical treatments. However, ten patients (9.61%) who developed refractory genital human papillomavirus (<i>n</i> = 2), melanocytic nevus (<i>n</i> = 3), dysplastic nevi (<i>n</i> = 3), fibrous papules (<i>n</i> = 1), and molluscum contagiosum (<i>n</i> = 1) had to discontinue their treatment.</p><p><strong>Conclusion: </strong>Fingolimod treatment in patients with multiple sclerosis is associated with a range of dermatologic findings, predominantly mild to moderate in severity. This population warrants awareness of these potential adverse events and regular follow-up.</p>","PeriodicalId":18961,"journal":{"name":"Multiple Sclerosis Journal - Experimental, Translational and Clinical","volume":"11 3","pages":"20552173251369990"},"PeriodicalIF":2.3,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12374027/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144962071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Optimizing premedications for multiple sclerosis patients treated with ocrelizumab: A randomized controlled trial. 优化ocrelizumab治疗多发性硬化症患者的预用药:一项随机对照试验。
IF 2.3
Multiple Sclerosis Journal - Experimental, Translational and Clinical Pub Date : 2025-08-10 eCollection Date: 2025-07-01 DOI: 10.1177/20552173251359074
Naghmeh Abbasi Kasbi, Ali Rezaei, Reyhaneh Montazeri, Sahar Nikkhah Bahrami, Nasim Rezaeimanesh, Melika Arab Bafrani, Sajjad Ghane Ezabadi, Kosar Kohandel, Faezeh Khodaie, Shima Jahani, Abdorreza Naser Moghadasi, Amirreza Azimi Saeen, Samira Navardi, Hora Heidari, Zahra Ebadi, Mohammad Ali Sahraian
{"title":"Optimizing premedications for multiple sclerosis patients treated with ocrelizumab: A randomized controlled trial.","authors":"Naghmeh Abbasi Kasbi, Ali Rezaei, Reyhaneh Montazeri, Sahar Nikkhah Bahrami, Nasim Rezaeimanesh, Melika Arab Bafrani, Sajjad Ghane Ezabadi, Kosar Kohandel, Faezeh Khodaie, Shima Jahani, Abdorreza Naser Moghadasi, Amirreza Azimi Saeen, Samira Navardi, Hora Heidari, Zahra Ebadi, Mohammad Ali Sahraian","doi":"10.1177/20552173251359074","DOIUrl":"10.1177/20552173251359074","url":null,"abstract":"<p><strong>Background: </strong>Multiple sclerosis (MS), a chronic neurological disease, is typically managed with disease-modifying therapies (DMTs) to reduce relapse rates and slow disease progression. Some of these DMTs can cause infusion-related reactions (INRRs), which range from mild symptoms to severe allergic reactions. Corticosteroids are commonly used in premedication regimens to mitigate INRRs. However, long-term use of corticosteroids carries health risks. This study aims to compare the effectiveness of a standard corticosteroid regimen with an adjusted, low-dose regimen in reducing INRRs among people living with MS, receiving ocrelizumab (Xacrel), with the goal of optimizing safety while minimizing corticosteroid exposure.</p><p><strong>Methods: </strong>In a single-blind, randomized, parallel-group clinical trial conducted at Sina Hospital, 200 adult patients with MS who had previously received ocrelizumab were recruited and randomly assigned to either a standard or adjusted premedication regimen groups. The standard regimen group (n = 101) received 100 mg intravenous (IV) methylprednisolone, along with cetirizine and acetaminophen tablets as premedication, while the adjusted regimen group (n = 99) received a reduced dose of 8 mg IV dexamethasone. The incidence of INRRs and their severity was monitored up to 1-hour post-infusion and 24-h post-infusion. Statistical analyses, including Chi-square tests and logistic regression, were used to evaluate the frequency of INRRs, characterize symptom profiles, and identify potential predictive factors for INRRs occurrence.</p><p><strong>Results: </strong>Overall, the standard premedication demonstrated more efficacy in reducing the occurrence of INRRs, while the adjusted regimen group showed a significantly higher incidence of INRRs compared to the standard regimen group (78.8% vs. 40.6%, p-value <0.01). Specific INRRs symptoms, such as itching (29.3% in the adjusted group vs. 8.3% in the standard group, p-value <0.01) and throat irritation (65.7% vs. 31.7%, p-value <0.01), were notably more frequent in the adjusted regimen group. Most INRRs were mild to moderate in severity in both groups. There was no statistically significant difference in the occurrence of severe reactions between the two groups. Notably, a history of INRRs from previous infusions was identified as a strong predictor of INRRs in the current study, with an odds ratio of 6.27 (95% CI: 3.36-11.70), highlighting the importance of patients' history in managing INRRs risk.</p><p><strong>Conclusions: </strong>The standard premedication regimen was more effective in reducing INRRs in people living with MS, receiving Xacrel compared to the reduced corticosteroid regimen. However, the findings suggest that a lower corticosteroid regimen may be beneficial for some patients, as there was no significant difference in the incidence of severe INRRs between the two groups.</p>","PeriodicalId":18961,"journal":{"name":"Multiple Sclerosis Journal - Experimental, Translational and Clinical","volume":"11 3","pages":"20552173251359074"},"PeriodicalIF":2.3,"publicationDate":"2025-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12340190/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144835786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信